Drug or treatment

Pembrolizumab clinical trials

• 394Clinical trials
• 3New in 30 days
• 65Countries

Newest trials

All recruiting trials (newest 150 of 394)

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer

  This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.

  Recruiting at 3 sites Comprehensive Cancer Center Munich (CCCM) · Munich, Bavaria and 2 other locations · NCT07870577

• Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer

  This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07850791

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin in untreated locally advanced or metastatic urothelial cancer

  This trial tests if adding ivonescimab to enfortumab vedotin works better than pembrolizumab plus enfortumab vedotin for people with untreated locally advanced or metastatic urothelial cancer.

  Recruiting at 2 sites Phase 2/3 Summit Therapeutics · Phoenix, Arizona and 6 other locations · NCT07815665

• VVD-133214 with Pembrolizumab in advanced colorectal cancer

  This study tests whether adding VVD-133214 to pembrolizumab helps people with advanced colorectal cancer better than pembrolizumab alone.

  Recruiting at 9 sites Phase 2 Vividion Therapeutics, Inc. · Tucson, Arizona and 121 other locations · NCT07811193

• Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer

  This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.

  Recruiting at 3 sites Phase 2 Solstice Oncology, Inc. · Los Angeles, California and 29 other locations · NCT07808151

• Ficerafusp alfa (BCA101) with pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC: alternative dosing vs weekly dosing

  This study tests whether a different dosing approach of ficerafusp alfa plus pembrolizumab works as well as the standard weekly dosing in adults with newly diagnosed or recurrent/metastatic PD-L1-positive head and neck cancer.

  Recruiting at 7 sites Phase 2 Bicara Therapeutics · Fort Myers, Florida and 6 other locations · NCT07807163

• Proton or Photon Radiotherapy Added to Pembrolizumab Before Surgery for Advanced or Recurrent Oral Cavity Cancer

  This phase 2 trial tests whether adding proton SFRT or SBRT to pembrolizumab before surgery helps patients with advanced or recurrent oral cavity cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07783581

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• ABBV-1480 plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer

  This study tests whether ABBV-1480 with platinum-based chemotherapy can work better than pembrolizumab with chemotherapy for adults with certain stages of non-small cell lung cancer.

  Recruiting at 2 sites Phase 3 AbbVie · Fort Wayne, Indiana and 1 other locations · NCT07756645

• STX-003 in advanced solid tumors given by IV, alone or with pembrolizumab

  This study tests STX-003, given by IV, to see if it is safe and potentially effective for patients with advanced solid tumors, either alone or with pembrolizumab.

  Recruiting at 4 sites Phase 1/2 Strand Therapeutics Inc. · Scottsdale, Arizona and 3 other locations · NCT07751042

• Zanzalintinib alone or with Pembrolizumab and Berahyaluronidase Alfa in colorectal cancer with molecular residual disease

  This trial tests whether zanzalintinib alone or with pembrolizumab and berahyaluronidase alfa can help people with stage II/III colorectal cancer who still have MRD detected by a Signatera test after surgery.

  Recruiting at 13 sites Phase 3 Exelixis · Council Bluffs, Iowa and 12 other locations · NCT07750158

• ARV-6723 alone or with pembrolizumab in adults with advanced solid tumors

  This study tests ARV-6723, by itself or with pembrolizumab, to see if it is safe and could help the immune system fight advanced solid tumors in adults.

  Recruiting at 4 sites Phase 1/2 Arvinas Inc. · New York, New York and 3 other locations · NCT07749586

• Telisotuzumab Adizutecan with Pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer

  This study tests a combination treatment to see if it helps people with newly diagnosed recurrent or metastatic head and neck squamous cell carcinoma who express the c-Met protein.

  Recruiting at 5 sites Phase 2 AbbVie · Duarte, California and 4 other locations · NCT07744126

• Sacituzumab tirumotecan with or without pembrolizumab in ovarian clear cell cancer that has come back or spread

  This phase II study tests Sacituzumab tirumotecan alone or with pembrolizumab in adults whose ovarian clear cell cancer has recurred or spread after prior PD-1 therapy.

  Recruiting Phase 2 Tufts Medical Center · Boston, Massachusetts · NCT07718854

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

• A combination therapy with ASP2138 and standard chemotherapy plus pembrolizumab for advanced stomach and GEJ cancer

  This study tests ASP2138 along with pembrolizumab and chemotherapy to see if it helps people with advanced, inoperable, or metastatic gastric or GEJ cancer that is HER2-negative and CLDN18.2-positive.

  Recruiting at 12 sites Phase 3 Astellas Pharma Inc · Saint Louis Park, Minnesota and 11 other locations · NCT07673887

• Enfortumab Vedotin, Pembrolizumab, and Quemliclustat for unresectable or metastatic urothelial cancer

  This trial tests a three-drug combination to see if it can safely treat unresectable or metastatic urothelial cancer in adults.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07667335

• Aglatimagene Besadenovec with Prodrug and Pembrolizumab vs Docetaxel for Advanced Non-Squamous NSCLC

  This phase 3 trial tests whether giving aglatimagene besadenovec with a prodrug and pembrolizumab works better than standard chemotherapy (docetaxel) for adults with stage IV non-squamous NSCLC that progressed on pembrolizumab.

  Recruiting Phase 3 Candel Therapeutics, Inc. · New York, New York · NCT07660094

• Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

  This registry follows people with persistent, recurrent, or metastatic cervical cancer who are treated with pembrolizumab-containing regimens to see how well it works in real-world care.

  Recruiting at 3 sites Phase 4 University Medical Center Groningen · Amsterdam and 10 other locations · NCT07645625

• Sitagliptin Plus Pembrolizumab in Advanced Renal Cell Carcinoma and Melanoma

  This study tests whether adding sitagliptin to pembrolizumab is safe and might help people whose advanced kidney cancer or melanoma stopped responding to prior PD-1/PD-L1 therapy.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07634380

• 64Cu-DOTA-Pembrolizumab PET to See If Treatment Is Working in Stage IV NSCLC

  This study tests a new PET imaging agent paired with pembrolizumab to see if it can show which tumors are still responding in adults with stage IV NSCLC who are already receiving pembrolizumab.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07619599

• Pembrolizumab and Lenvatinib for recurrent endometrial cancer that has progressed after first-line therapy

  This trial tests a combination of pembrolizumab and lenvatinib to see if it can help adults with recurrent mismatch repair-proficient endometrial cancer after failure of initial platinum-based chemo and immunotherapy.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07594015

• Consolidative therapy after initial response in advanced bladder cancer

  This pilot trial tests adding radiation or surgery after a good response to EV + pembrolizumab in unresectable or oligometastatic muscle-invasive bladder cancer to see if residual disease can be eliminated or delayed from growing.

  Recruiting Phase 1/2 University of Washington · Seattle, Washington · NCT07579195

• PF-08634404 plus chemotherapy in adults with advanced or recurrent pMMR endometrial cancer

  This study tests whether PF-08634404 added to standard chemotherapy helps adults with advanced or recurrent pMMR endometrial cancer more than pembrolizumab plus chemotherapy.

  Recruiting at 47 sites Phase 3 Pfizer · Jupiter, Florida and 53 other locations · NCT07578649

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

• PRTX007-003 with pembrolizumab before surgery for stage III melanoma

  This study tests whether adding the oral drug PRTX007 to pembrolizumab before surgery helps patients with resectable stage III melanoma respond better without extra safety risks.

  Recruiting at 3 sites Phase 2 Primmune Therapeutics, Inc. · Waratah, New South Wales and 6 other locations · NCT07565285

• Adjuvant intismeran (V940) with or without pembrolizumab plus berahyaluronidase alfa for high‑risk Stage I non‑small cell lung cancer after surgery

  This trial will try intismeran (V940) alone or together with subcutaneous pembrolizumab plus berahyaluronidase alfa to help prevent recurrence in people with completely removed high‑risk Stage I non‑small cell lung cancer.

  Recruiting at 126 sites Phase 3 Merck Sharp & Dohme LLC · Sacramento, California and 125 other locations · NCT07513376

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Pembrolizumab with ultrasound-induced microbubble cavitation for recurrent or metastatic head and neck cancer

  We will try giving pembrolizumab together with ultrasound-triggered microbubbles to people with HPV-negative recurrent or metastatic head and neck cancer to help the drug reach tumors and improve response.

  Recruiting Phase 1 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07501650

• Zongertinib with or without pembrolizumab and platinum chemotherapy in HER2-mutant NSCLC

  This trial tests whether zongertinib can be tolerated when given with platinum-based chemotherapy, with or without pembrolizumab, in adults with advanced HER2-mutant non-squamous NSCLC.

  Recruiting at 19 sites Phase 2 Boehringer Ingelheim · St Leonards, New South Wales and 19 other locations · NCT07486817

• Postbiotix-HLA™ with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.

  This trial will test whether taking the postbiotic supplement Postbiotix-HLA™ with first-line pembrolizumab reduces immune-related side effects and alters microbiota in people with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting Phase 2 Gruppo Oncologico del Nord-Ovest · Rozzano, Milano · NCT07485296

• GB-4362 combined with enfortumab vedotin and pembrolizumab for advanced urothelial cancer

  This study will test adding GB-4362 to enfortumab vedotin and pembrolizumab to see if it lowers treatment-related side effects like nerve damage in adults with advanced or metastatic urothelial cancer.

  Recruiting at 10 sites Phase 1 Generate Biomedicines · Duarte, California and 9 other locations · NCT07484022

• Enfortumab vedotin plus pembrolizumab to help people with muscle-invasive bladder cancer keep their bladder

  This trial tests whether giving enfortumab vedotin together with pembrolizumab can let people with muscle-invasive bladder cancer avoid bladder removal.

  Recruiting at 68 sites Phase 2 Astellas Pharma Inc · Little Rock, Arkansas and 67 other locations · NCT07475806

• BC3195 plus pembrolizumab in advanced solid tumors

  This trial tests whether adding BC3195 to pembrolizumab is safe and shows preliminary activity in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1/2 Biocity Biopharmaceutics Co., Ltd. · Guangzhou, Guangdong · NCT07469774

• Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma

  This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07465276

• Neoadjuvant CADI-05 with pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma

  This will test whether adding weekly CADI-05 skin injections to pembrolizumab before surgery helps adults with resectable locally advanced head and neck squamous cell cancer.

  Recruiting at 2 sites Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07455032

• ILKN421H plus pembrolizumab in advanced NSCLC

  This study tests whether ILKN421H given with pembrolizumab is safe and active in adults with locally advanced or metastatic NSCLC who have already tried other treatments.

  Recruiting at 2 sites Phase 2 iLeukon Therapeutics, Inc. · Los Angeles, California and 1 other locations · NCT07452224

• One-dose pembrolizumab before surgery for high-risk localized melanoma

  This trial gives one dose of pembrolizumab six weeks before surgery to see if it helps adults with high‑risk melanoma that appears confined on scans.

  Recruiting Phase 2 Universitair Ziekenhuis Brussel · Jette, Brussels Capital · NCT07448831

• Adjuvant calderasib with subcutaneous pembrolizumab plus berahyaluronidase alfa for completely resected KRAS G12C stage IIA–IIIB (N2) NSCLC

  This trial tests whether adding the oral KRAS G12C inhibitor calderasib to subcutaneous pembrolizumab plus berahyaluronidase alfa helps prevent recurrence in people with completely resected stage IIA–IIIB (N2) KRAS G12C non‑small cell lung cancer.

  Recruiting at 122 sites Phase 3 Merck Sharp & Dohme LLC · Ciudad Autónoma de Buenos Aires, Buenos Aires and 121 other locations · NCT07431827

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Comparing chemo‑immunotherapy options for metastatic NSCLC with PD‑L1 <50%

  This project will see if two common first‑line chemo‑immunotherapy approaches give different survival and quality‑of‑life results for adults with metastatic NSCLC whose tumors have PD‑L1 under 50%.

  Recruiting at 2 sites Gazi University · Ankara and 1 other locations · NCT07394062

• EIK1001 with pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer

  This study tests whether adding EIK1001 to pembrolizumab plus standard chemotherapy can help people with stage 4 NSCLC.

  Recruiting at 42 sites Phase 2/3 Eikon Therapeutics · Daphne, Alabama and 41 other locations · NCT07365319

• SCTB14 as first-line therapy for advanced NSCLC

  This trial will test whether SCTB14 works better than pembrolizumab as first treatment for adults with unresectable locally advanced or metastatic, driver-gene–negative NSCLC whose tumors have PD-L1 TPS ≥10%.

  Recruiting Phase 3 Sinocelltech Ltd. · Shanghai, Shanghai Municipality · NCT07362459

• Pumitamig vs pembrolizumab for first-line advanced NSCLC with PD‑L1 ≥50% (ROSETTA Lung-202)

  This will test if pumitamig works better than pembrolizumab as the first treatment for people with advanced non-small cell lung cancer and PD‑L1 levels of 50% or higher.

  Recruiting at 180 sites Phase 3 Bristol-Myers Squibb · Daphne, Alabama and 282 other locations · NCT07361510

• One-dose pembrolizumab before surgery for thick primary (Stage IIb/c) melanoma

  This trial tests whether giving one dose of pembrolizumab before surgery helps adults with biopsy-proven Stage IIb/c primary cutaneous melanoma.

  Recruiting Phase 2 Vastra Gotaland Region · Gothenburg · NCT07349303

• ATG-022 plus pembrolizumab, with or without CAPOX chemotherapy, for CLDN18.2-positive, HER2-negative advanced stomach or gastroesophageal junction cancer

  This trial will try ATG-022 together with pembrolizumab, with or without CAPOX chemotherapy, to see if it helps people with CLDN 18.2-positive, HER2-negative advanced or metastatic gastric or gastroesophageal junction cancer who are PD-L1 positive.

  Recruiting at 26 sites Phase 1/2 Antengene Corporation · Hefei, Anhui and 29 other locations · NCT07327229

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Pembrolizumab treatment for Japanese children with solid tumors or lymphomas and Japanese adults with Merkel cell carcinoma

  This study will try pembrolizumab in Japanese children with solid tumors or lymphomas and in Japanese adults with Merkel cell carcinoma to learn about safety, how the drug moves through the body, and whether tumors shrink.

  Recruiting at 7 sites Phase 1/2 Merck Sharp & Dohme LLC · Nagoya, Aichi-ken and 6 other locations · NCT07302347

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• Pembrolizumab plus lenvatinib for vulvar cancer (MITO VULVA-01)

  This trial will test whether combining pembrolizumab with lenvatinib helps people with advanced, recurrent, or unresectable vulvar cancer.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples · NCT07290894

• Zanzalintinib plus pembrolizumab for select advanced soft-tissue sarcomas

  This trial will test whether combining zanzalintinib with pembrolizumab can help control certain advanced or metastatic soft-tissue sarcomas in adults.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283731

• Preoperative chemotherapy with pembrolizumab and a low or high radiation boost for node-positive triple-negative breast cancer

  This study tests whether giving a low or high radiation boost together with preoperative chemotherapy and pembrolizumab can better activate the immune system in people with node‑positive triple‑negative breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07276880

• Amivantamab added to pembrolizumab and platinum chemotherapy versus pembrolizumab with platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial will see if adding amivantamab to pembrolizumab and platinum‑based chemotherapy helps adults with recurrent or metastatic head and neck squamous cell carcinoma who have not yet had systemic treatment in the metastatic setting.

  Recruiting at 205 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 204 other locations · NCT07276399

• Pembrolizumab plus chemotherapy for frail adults with classical Hodgkin lymphoma who can't get standard treatment

  This phase II trial tests whether adding pembrolizumab to gemcitabine-based chemotherapy (with possible brentuximab vedotin and dacarbazine) helps frail adults newly diagnosed with classical Hodgkin lymphoma who are ineligible for standard anthracycline-based therapy.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07275216

• BL-M07D1 plus pembrolizumab for advanced HER2‑overexpressing non-squamous NSCLC

  This treatment combines BL-M07D1 with pembrolizumab to see if it helps people with unresectable locally advanced or metastatic HER2‑overexpressing non‑squamous non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07264816

• Ivonescimab with or without ligufalimab versus pembrolizumab as first-line treatment for recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma

  This study tests whether ivonescimab alone or with ligufalimab works as a first-line treatment for PD-L1‑positive recurrent or metastatic head and neck cancer, compared with pembrolizumab.

  Recruiting Phase 3 Groupe Oncologie Radiotherapie Tete et Cou · Le Havre · NCT07264075

• EIK1005 (Werner helicase inhibitor) alone or with pembrolizumab for advanced MSI-H/dMMR and other solid tumors

  This trial tests whether EIK1005, given alone or together with pembrolizumab, can be safely given and help people with advanced solid tumors, especially MSI‑H/dMMR cancers.

  Recruiting at 44 sites Phase 1/2 Eikon Therapeutics · Los Angeles, California and 44 other locations · NCT07262619

• Weekly paclitaxel or nab-paclitaxel with pembrolizumab and mirabegron for recurrent ovarian cancer

  This study tests whether weekly paclitaxel or nab-paclitaxel combined with pembrolizumab and daily mirabegron can shrink tumors and be safe for adults with relapsed ovarian cancer.

  Recruiting Phase 2 Obstetrics & Gynecology Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07261683

• Lutetium-177 DGUL plus pembrolizumab in metastatic castration-resistant prostate cancer

  This study tests whether adding pembrolizumab to Lutetium-177 DGUL is safe and can help treat men with advanced prostate cancer that no longer responds to hormone therapy.

  Recruiting Phase 1 Cellbion Co., Ltd. · Seoul · NCT07244393

• Adding MK-3120 to enfortumab vedotin and pembrolizumab for advanced urothelial (bladder) cancer

  This study tests whether adding the investigational drug MK-3120 to standard enfortumab vedotin plus pembrolizumab helps people with locally advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 17 sites Phase 1/2 Merck Sharp & Dohme LLC · San Francisco, California and 16 other locations · NCT07232602

• ABX-001 alone or with pembrolizumab for advanced solid tumors

  This tests whether the new immunotherapy ABX-001, given alone or with pembrolizumab, is safe and shows signs of benefit in adults with advanced solid tumors that have stopped responding to prior treatments.

  Recruiting at 5 sites Phase 1 Abalos Therapeutics GmbH · Berlin and 4 other locations · NCT07231458

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Pembrolizumab maintenance after initial enfortumab vedotin plus pembrolizumab for frontline metastatic urothelial cancer

  This trial will test whether continuing pembrolizumab after an 18-week course of enfortumab vedotin plus pembrolizumab helps people with previously untreated metastatic urothelial carcinoma.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07221942

• Intismeran autogene plus pembrolizumab and chemotherapy for metastatic squamous non-small cell lung cancer

  This trial will test whether adding intismeran autogene to pembrolizumab and chemotherapy helps people with treatment‑naive metastatic squamous non‑small cell lung cancer live longer and keep their cancer from growing.

  Recruiting at 55 sites Phase 2 Merck Sharp & Dohme LLC · Tampa, Florida and 54 other locations · NCT07221474

• Vepugratinib with enfortumab vedotin and pembrolizumab for FGFR3‑altered advanced urothelial cancer

  This trial tests whether adding vepugratinib to enfortumab vedotin and pembrolizumab helps people with advanced or metastatic urothelial (bladder) cancer who have an FGFR3 genetic change, compared with placebo.

  Recruiting at 129 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 275 other locations · NCT07218380

• Sacituzumab tirumotecan plus pembrolizumab as first-line maintenance for metastatic cervical cancer

  This trial tests whether adding the antibody-drug conjugate sacituzumab tirumotecan to pembrolizumab (with or without bevacizumab) as maintenance treatment can help people with metastatic cervical cancer live longer or keep the cancer from growing.

  Recruiting at 191 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 190 other locations · NCT07216703

• CKD-512 alone and with pembrolizumab for advanced or metastatic solid tumors

  This study will try CKD-512 by itself and together with pembrolizumab in people with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Chong Kun Dang Pharmaceutical · Seoul · NCT07215637

• Oral JBI-802 alone or with pembrolizumab for non-small cell lung cancer with an STK11 mutation

  This will test whether taking oral JBI-802 by itself or together with pembrolizumab helps people with advanced non-small cell lung cancer that has an STK11 mutation.

  Recruiting Phase 2 The Christ Hospital · Cincinnati, Ohio · NCT07207395

• Adding bevacizumab to carboplatin, paclitaxel and pembrolizumab for pMMR, TP53‑mutated advanced or recurrent endometrial cancer

  This trial tests whether adding bevacizumab to carboplatin and paclitaxel with pembrolizumab helps people with pMMR, TP53‑mutated advanced or recurrent endometrial cancer live longer without the disease getting worse.

  Recruiting at 308 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 308 other locations · NCT07198074

• Calderasib plus subcutaneous pembrolizumab for KRAS G12C non-small cell lung cancer

  This trial will test whether adding the KRAS G12C drug calderasib to subcutaneous pembrolizumab helps people with advanced nonsquamous non‑small cell lung cancer live longer without the cancer growing compared with pembrolizumab plus chemotherapy.

  Recruiting at 221 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 224 other locations · NCT07190248

• SBRT with intratumoural pembrolizumab before neoadjuvant chemotherapy for high-risk breast cancer

  This study will test whether a short course of focused radiation plus two injections of pembrolizumab into the tumor before chemotherapy helps people with high‑risk invasive breast cancer respond better to treatment.

  Recruiting Phase 2 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario and 1 other locations · NCT07188246

• Neoadjuvant belzutifan, pembrolizumab, or both for clear cell kidney cancer

  We will see if giving belzutifan alone, pembrolizumab alone, or both before kidney surgery helps shrink locally advanced clear cell kidney cancer.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Ann Arbor, Michigan and 1 other locations · NCT07187778

• Zanidatamab with pembrolizumab and chemotherapy for HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma

  This trial tests whether adding zanidatamab to pembrolizumab plus chemotherapy helps people with untreated HER2- and PD-L1-positive metastatic gastroesophageal adenocarcinoma.

  Recruiting at 14 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Berlin and 19 other locations · NCT07176312

• CUE-101 with pembrolizumab for locally advanced HPV‑16 positive oropharyngeal cancer

  This trial tests whether CUE-101 alone or combined with pembrolizumab before definitive therapy helps people with newly diagnosed, locally advanced HPV‑16 positive oropharyngeal cancer who are HLA‑A*02:01 positive.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07172256

• M0324 alone or with pembrolizumab or mFOLFIRINOX chemotherapy for selected advanced solid tumors

  This trial tests whether the experimental drug M0324, given alone or with pembrolizumab or mFOLFIRINOX chemotherapy, is safe and shows early signs of benefit for people with advanced solid tumors that overexpress MUC-1.

  Recruiting at 5 sites Phase 1 EMD Serono · New Haven, Connecticut and 4 other locations · NCT07166601

• ABL103 plus pembrolizumab, with or without taxane, for advanced or metastatic solid tumors

  This trial will try ABL103 together with pembrolizumab, with or without a taxane chemotherapy, in adults with advanced or metastatic solid tumors who have relapsed on or cannot tolerate standard treatments.

  Recruiting at 2 sites Phase 1/2 ABL Bio, Inc. · Cleveland, Ohio and 5 other locations · NCT07158918

• HCB101 plus pembrolizumab for platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma

  This trial tests whether adding HCB101 to pembrolizumab is safe and helps people with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting at 3 sites Phase 1/2 Taipei Veterans General Hospital, Taiwan · Taoyuan, Guishan District and 2 other locations · NCT07136545

• Datopotamab deruxtecan plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin for advanced or metastatic urothelial carcinoma

  This trial will test whether datopotamab deruxtecan with carboplatin or cisplatin works better than gemcitabine with carboplatin or cisplatin for people with advanced urothelial carcinoma who progressed during or after enfortumab vedotin plus pembrolizumab.

  Recruiting at 29 sites Phase 2/3 Daiichi Sankyo · Fullerton, California and 99 other locations · NCT07129993

• APX-343A alone or with pembrolizumab for advanced solid tumors

  This Phase 1 trial will test whether APX-343A by itself or combined with the immunotherapy pembrolizumab is safe and shows early benefit in adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 Aptabio Therapeutics, Inc. · Seongnam and 2 other locations · NCT07123415

• IBI363 or pembrolizumab plus chemotherapy before surgery for resectable stage IB–III non-squamous non-small cell lung cancer

  This trial will see if giving IBI363 with chemotherapy or pembrolizumab with chemotherapy before surgery helps adults with resectable stage IB–III non-squamous non-small cell lung cancer and is safe.

  Recruiting Phase 2 Innovent Biologics (Suzhou) Co. Ltd. · Shenyang, Liaoning · NCT07122687

• Visugromab added to first-line immunochemotherapy for metastatic non-squamous NSCLC

  This trial tests whether adding visugromab to standard immunochemotherapy (pembrolizumab, pemetrexed, carboplatin) helps people with newly diagnosed metastatic non-squamous NSCLC who do not have targetable mutations.

  Recruiting at 51 sites Phase 2 CatalYm GmbH · Birmingham, Alabama and 50 other locations · NCT07098988

• EVM14 alone and with pembrolizumab for selected advanced solid tumors

  This trial tests whether the cancer vaccine EVM14, given by muscle injection alone or together with pembrolizumab, is safe and provokes an immune response in people with selected advanced solid tumors.

  Recruiting at 7 sites Phase 1/2 Everest Medicines (China) Co.,Ltd. · New York, New York and 6 other locations · NCT07095868

• Pembrolizumab for ultra-rare sarcomas

  This trial will test whether pembrolizumab can help people with certain ultra-rare sarcomas and cause only mild side effects.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07089992

• Therapeutic plasma exchange plus enfortumab vedotin and pembrolizumab for bladder and upper urinary tract urothelial cancer

  This trial will test whether doing a therapeutic plasma exchange before giving enfortumab vedotin (an antibody‑drug conjugate) and pembrolizumab (an immune checkpoint inhibitor) helps people with metastatic or refractory urothelial (bladder or upper tract) cancer who have progressed on prior therapies.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07087860

• Pembrolizumab plus odetiglucan for liver‑predominant metastatic colorectal adenocarcinoma

  This will test whether pembrolizumab combined with odetiglucan is safe and helps adults whose colorectal cancer has spread mainly to the liver after standard chemotherapy and targeted drugs.

  Recruiting Phase 2 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07082439

• BMS-986504 plus pembrolizumab and chemotherapy for first-line metastatic NSCLC with MTAP deletion

  This study will test whether adding BMS-986504 to pembrolizumab and platinum chemotherapy helps people with first-line metastatic NSCLC who have a homozygous MTAP deletion.

  Recruiting at 191 sites Phase 2/3 Bristol-Myers Squibb · Anchorage, Alaska and 320 other locations · NCT07063745

• Induction pembrolizumab with carboplatin/paclitaxel before chemoradiation and pembrolizumab maintenance for high‑risk locally advanced cervical cancer

  This phase III trial tests whether giving pembrolizumab with carboplatin and paclitaxel before chemoradiation, then continuing pembrolizumab as maintenance, helps people with locally advanced high‑risk cervical cancer stay free of progression longer than starting pembrolizumab during chemoradiation.

  Recruiting at 340 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 346 other locations · NCT07061977

• BL-B01D1 plus pembrolizumab, with or without bevacizumab, for recurrent or metastatic cervical and endometrial cancer

  This trial will try a combination of BL-B01D1 and pembrolizumab, with or without bevacizumab, in adults with recurrent or metastatic cervical or endometrial cancer to see if it shrinks tumors or controls the disease.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07054567

• Gemcitabine plus carboplatin after progression on enfortumab vedotin and pembrolizumab for advanced urothelial cancer

  This trial tests whether the chemotherapy combination gemcitabine and carboplatin can shrink or control advanced urothelial cancer in people whose cancer got worse after enfortumab vedotin plus pembrolizumab.

  Recruiting at 2 sites Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07043972

• Adding CBM588 to pembrolizumab after surgery for kidney cancer

  This trial tests whether adding CBM588 to pembrolizumab after kidney cancer surgery helps prevent recurrence compared with pembrolizumab alone.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07037004

• Hormone therapy with darolutamide and pembrolizumab before prostate removal, then pembrolizumab after surgery for high-risk prostate cancer

  This trial will test whether giving androgen-deprivation therapy plus darolutamide and pembrolizumab before prostate removal, followed by pembrolizumab after surgery, helps men with genomically defined high-risk localized prostate cancer.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07027124

• Re‑radiation with chemotherapy plus pembrolizumab versus pembrolizumab (± chemotherapy) for recurrent PD‑L1 positive head and neck cancer

  This trial tests whether adding re‑radiation with chemotherapy followed by pembrolizumab helps people with PD‑L1 positive (CPS≥1) locoregionally recurrent head and neck cancer live longer than pembrolizumab alone (with or without chemotherapy).

  Recruiting at 20 sites Phase 3 Universität des Saarlandes · Berlin and 23 other locations · NCT07026474

• ctDNA-guided therapy for relapsed or refractory Hodgkin lymphoma using pembrolizumab with GVD

  This study tests a pembrolizumab-based regimen plus chemotherapy in adults with relapsed or refractory classic Hodgkin lymphoma to see if ctDNA can guide treatment response and consolidation choices.

  Recruiting Phase 2 University of California, San Francisco · Davis, California and 5 other locations · NCT07021989

• Neoadjuvant pembrolizumab with FLOT chemotherapy and short-course radiation for locally advanced gastroesophageal junction cancer

  This treatment plan will test whether pembrolizumab plus FLOT chemotherapy given before and after a short course of radiation can let some patients with locally advanced gastroesophageal junction adenocarcinoma avoid surgery or improve cancer control.

  Recruiting Phase 2 National Cancer Center Hospital East · Kashiwa, Chiba · NCT07018570

• GT103 plus pembrolizumab for advanced STK11‑mutant non‑small cell lung cancer

  This trial tests whether adding GT103 to pembrolizumab can help adults with advanced or metastatic STK11‑mutant non‑small cell lung cancer.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT07017829

• Pembrolizumab for advanced cutaneous sarcomas (excluding angiosarcoma)

  This will try pembrolizumab every three weeks in adults with advanced or metastatic skin-based sarcomas that are not angiosarcoma.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 2 other locations · NCT07007273

• KQB168 alone or with pembrolizumab for adults with advanced solid tumors

  This will test whether daily KQB168, alone or together with pembrolizumab, can shrink tumors and is safe for adults with advanced solid cancers that have progressed after prior immunotherapy.

  Recruiting at 15 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 14 other locations · NCT06994806

• New treatment options for advanced endometrial cancer

  This study is testing a new combination of treatments for advanced endometrial cancer to see if it can help patients live longer without their cancer getting worse compared to standard chemotherapy.

  Recruiting at 205 sites Phase 3 AstraZeneca · Tucson, Arizona and 256 other locations · NCT06989112

• SSGJ-707 versus pembrolizumab for advanced non-small cell lung cancer

  This Phase III test will see if SSGJ-707 works as well as or better than pembrolizumab for adults with stage IIIB/IIIC (not suitable for radical therapy) or stage IV non-small cell lung cancer whose tumors have PD-L1 TPS ≥1% and who have ECOG performance status 0–1 and no prior systemic therapy.

  Recruiting Phase 3 Shenyang Sunshine Pharmaceutical Co., LTD. · Shanghai · NCT06980272

• Combination therapy for recurrent triple-negative breast cancer

  This study is testing a combination of two drugs, pembrolizumab and paclitaxel, to see if they can help people with recurrent triple-negative breast cancer who haven't had chemotherapy before.

  Recruiting at 14 sites Phase 2 Japanese Foundation for Cancer Research · Nagoya, Aichi-ken and 13 other locations · NCT06976944

• Sacituzumab tirumotecan plus pembrolizumab and chemotherapy for high-risk early triple-negative and HR-low/HER2-negative breast cancer

  This trial will test whether adding sacituzumab tirumotecan and pembrolizumab to chemotherapy helps people with high‑risk early-stage triple‑negative or HR‑low/HER2‑negative breast cancer have fewer cancer cells in their tumors and lymph nodes before surgery.

  Recruiting at 331 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 334 other locations · NCT06966700

• BL-B01D1 plus a TKI, with or without pembrolizumab, for advanced kidney cancer

  This trial will test whether adding the experimental drug BL-B01D1 to a standard TKI—with or without the immunotherapy pembrolizumab—helps people with locally advanced or metastatic kidney cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06962787

• Evaluating VIR-5525 and its combination with Pembrolizumab for advanced solid tumors

  This study is testing a new treatment called VIR-5525, alone and with another drug called pembrolizumab, to see if it can help people with advanced solid tumors that have a specific protein called EGFR.

  Recruiting at 4 sites Phase 1 Vir Biotechnology, Inc. · Scottsdale, Arizona and 3 other locations · NCT06960395

• Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone for pMMR endometrial cancer

  This trial tests whether adding sacituzumab tirumotecan to pembrolizumab helps people with advanced or recurrent mismatch repair–proficient endometrial cancer live longer without their cancer getting worse compared to pembrolizumab alone.

  Recruiting at 266 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 270 other locations · NCT06952504

• IFx-Hu2.0 with pembrolizumab for advanced or metastatic Merkel cell carcinoma

  This will test whether injecting IFx-Hu2.0 into a tumor before giving pembrolizumab helps adults with advanced or metastatic Merkel cell carcinoma respond better than pembrolizumab alone.

  Recruiting at 18 sites Phase 2/3 TuHURA Biosciences, Inc. · Los Angeles, California and 17 other locations · NCT06947928

• IFx-Hu2.0 plus pembrolizumab for advanced or metastatic Merkel cell carcinoma

  This will test whether injecting IFx-Hu2.0 into a visceral tumor together with pembrolizumab is safe and doable for adults with advanced or metastatic Merkel cell carcinoma who have not had prior immune checkpoint inhibitors.

  Recruiting at 2 sites Phase 1 TuHURA Biosciences, Inc. · Tampa, Florida and 1 other locations · NCT06940440

• Neoadjuvant gemcitabine and cisplatin with perioperative pembrolizumab vs upfront surgery for cancers of the bile ducts

  This trial tests whether giving chemotherapy with pembrolizumab before surgery helps people with resectable or borderline resectable extrahepatic cholangiocarcinoma see if they have better outcomes than going straight to surgery.

  Recruiting Phase 2/3 Amsterdam UMC, location VUmc · Amsterdam · NCT06923475

• Using mistletoe extract with pembrolizumab for treating triple negative breast cancer

  This study is testing if adding mistletoe extract to pembrolizumab can help adults with triple negative breast cancer feel better after surgery.

  Recruiting Phase 4 Ilsan Cha hospital · Goyang-si, Gyeonggi-do · NCT06920810

• Zanzalintinib with pembrolizumab and cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial tests whether adding the oral drug zanzalintinib to pembrolizumab and cetuximab is safe and finds the best dose for adults with recurrent or metastatic head and neck squamous cell cancer.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT06912087

• Zolbetuximab plus pembrolizumab and chemotherapy for stomach and gastroesophageal junction cancer

  This trial will test whether adding zolbetuximab to pembrolizumab and standard chemotherapy helps adults with Claudin 18.2-positive, HER2-negative locally advanced or metastatic stomach or gastroesophageal junction cancer.

  Recruiting at 187 sites Phase 3 Astellas Pharma Inc · Birmingham, Alabama and 252 other locations · NCT06901531

• Trastuzumab deruxtecan plus pembrolizumab versus platinum chemotherapy plus pembrolizumab for first-line HER2‑overexpressing non‑squamous NSCLC

  This trial will test whether combining trastuzumab deruxtecan with pembrolizumab works better than standard platinum‑based chemotherapy plus pembrolizumab as first treatment for adults with HER2‑overexpressing, PD‑L1 low (<50%) advanced non‑squamous NSCLC.

  Recruiting at 246 sites Phase 3 Daiichi Sankyo · Anchorage, Alaska and 245 other locations · NCT06899126

• VO plus pembrolizumab for angiosarcoma

  This study tests whether injecting Vusolimogene Oderparepvec (VO) into tumors, together with pembrolizumab, can help people with advanced angiosarcoma who have already tried other immunotherapies.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT06898970

• Morning vs Flexible Timing Pembrolizumab in Metastatic Non-Small Cell Lung Cancer

  This study tests whether giving pembrolizumab in the morning is better or the same as standard timing for people with metastatic non-small cell lung cancer who are eligible for this treatment.

  Recruiting Phase 2 AHS Cancer Control Alberta · Edmonton, Alberta · NCT06882174

• Combining adagrasib, pembrolizumab, and chemotherapy for lung cancer with a specific mutation

  This study is testing a new treatment combining adagrasib, pembrolizumab, and chemotherapy to see if it helps people with a specific type of lung cancer that has a KRAS G12C mutation.

  Recruiting at 303 sites Phase 3 Mirati Therapeutics Inc. · Birmingham, Alabama and 316 other locations · NCT06875310

• Autologous tumor membrane vesicle (TMV) vaccine alone or with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

  This trial tests whether a vaccine made from a patient's own tumor (TMV), given alone or with pembrolizumab, can help people with recurrent or metastatic head and neck squamous cell carcinoma who had tumor tissue banked at surgery.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT06868433

• Comparing rilvegostomig and pembrolizumab for treating advanced lung cancer

  This study is testing whether a new drug called rilvegostomig works better than pembrolizumab for treating advanced lung cancer in patients whose tumors have a specific marker.

  Recruiting at 247 sites Phase 3 AstraZeneca · La Mesa, California and 303 other locations · NCT06868277

• Nemtabrutinib plus pembrolizumab for Richter transformation (DLBCL subtype)

  This phase II trial tests whether combining nemtabrutinib and pembrolizumab can shrink tumors and help people whose chronic lymphocytic leukemia has transformed into diffuse large B‑cell lymphoma (Richter transformation).

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06863402

• Cetuximab with or without weekly paclitaxel after progression on pembrolizumab plus platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial tests whether adding weekly paclitaxel to cetuximab helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after first‑line pembrolizumab plus platinum/5‑FU.

  Recruiting at 16 sites Phase 2 Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Santiago de Compostela, A Coruña and 16 other locations · NCT06856213

• Neoadjuvant ADG126 plus pembrolizumab for stage II–III colorectal cancer

  This study will try two pre-surgery doses of ADG126 together with pembrolizumab for people with stage II or III colorectal cancer to see if the combination is safe and can shrink tumors before surgery.

  Recruiting Phase 2 National University Hospital, Singapore · Singapore · NCT06846268

• Treatment for triple-negative breast cancer using sacituzumab tirumotecan and pembrolizumab

  This study is testing if a new treatment combining sacituzumab tirumotecan and pembrolizumab can help people with triple-negative breast cancer live longer and keep their cancer from getting worse compared to regular chemotherapy.

  Recruiting at 274 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 284 other locations · NCT06841354

• Combining endoscopic ultrasound radiofrequency ablation with immunotherapy for advanced pancreatic cancer

  This study is testing a new treatment that combines a special type of ultrasound therapy with chemotherapy and immunotherapy to see if it helps people with advanced pancreatic cancer live better and longer.

  Recruiting Phase 2 The University of Texas Health Science Center, Houston · Houston, Texas · NCT06831136

• Datopotamab-deruxtecan with carboplatin and pembrolizumab for treatment‑naive NSCLC that has spread to the brain

  This trial will try giving datopotamab-deruxtecan together with carboplatin and pembrolizumab to adults with metastatic non‑small cell lung cancer that has spread to the brain and has no targetable mutations.

  Recruiting at 13 sites Phase 2 Latin American Cooperative Oncology Group · Fortaleza, Ceará and 12 other locations · NCT06822543

• Combination treatment for muscle-invasive bladder cancer

  This study is testing a new combination of two medications to see if they can help people with muscle-invasive bladder cancer avoid surgery and improve their treatment outcomes.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · Duarte, California and 4 other locations · NCT06809140

• New treatment approach for high-risk early-stage breast cancer

  This study is testing a new combination of treatments for people with high-risk early-stage triple-negative breast cancer to see if it can shrink tumors more than the usual treatment before surgery.

  Recruiting at 17 sites Phase 2 Merck Sharp & Dohme LLC · Santa Monica, California and 16 other locations · NCT06797635

• Combining PYX-201 with Pembrolizumab for Advanced Solid Tumors

  This study is testing a new combination of two cancer treatments, PYX-201 and pembrolizumab, to see how well they work and how safe they are for people with advanced solid tumors like certain types of breast and head and neck cancers.

  Recruiting at 22 sites Phase 1/2 Pyxis Oncology, Inc · San Diego, California and 21 other locations · NCT06795412

• Combination treatment of pembrolizumab and high-dose pemetrexed for chordoma

  This study is testing a new combination of two drugs, pembrolizumab and high-dose pemetrexed, to see if it can help people with progressive chordoma, a rare cancer.

  Recruiting Phase 2 Saint John's Cancer Institute · Santa Monica, California · NCT06794645

• Divarasib plus pembrolizumab versus pembrolizumab with pemetrexed and platinum chemotherapy for first-line KRAS G12C advanced non-squamous non-small cell lung cancer

  This trial tests whether adding divarasib to pembrolizumab works better than standard pembrolizumab with pemetrexed plus carboplatin or cisplatin for adults with untreated, KRAS G12C-mutant advanced non-squamous non-small cell lung cancer.

  Recruiting at 295 sites Phase 3 Hoffmann-La Roche · Anchorage, Alaska and 298 other locations · NCT06793215

• Investigating OKN4395 and Pembrolizumab for Solid Tumors

  This study is testing a new drug called OKN4395, alone and with another drug called pembrolizumab, to see if it can help people with solid tumors who have run out of other treatment options.

  Recruiting at 10 sites Phase 1 Epkin · Beverly Hills, California and 9 other locations · NCT06789172

• Evaluating ficerafusp alfa with pembrolizumab for advanced head and neck cancer

  This study is testing a new treatment combining ficerafusp alfa and pembrolizumab to see if it helps people with advanced head and neck cancer feel better.

  Recruiting at 231 sites Phase 2/3 Bicara Therapeutics · Birmingham, Alabama and 230 other locations · NCT06788990

• Combination therapies for esophageal squamous cell carcinoma (KEYMAKER-U06 Substudy 06E)

  This trial will test pembrolizumab together with an investigational antibody-drug conjugate (I-DXd), with or without chemotherapy, as a first-line treatment for people with locally advanced unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting at 52 sites Phase 1/2 Merck Sharp & Dohme LLC · Pittsburgh, Pennsylvania and 51 other locations · NCT06780111

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Combining pembrolizumab with radiation therapy for bladder cancer treatment

  This study is testing if combining the immunotherapy drug pembrolizumab with radiation therapy can help people with non-muscle invasive bladder cancer do better than standard chemotherapy during treatment.

  Recruiting at 135 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 146 other locations · NCT06770582

• TQB2102 with immune therapy, with or without chemotherapy, for HER2‑positive advanced gastroesophageal cancer

  This test will see if TQB2102, a new HER2‑targeting antibody‑drug conjugate given with benmelstobart and sometimes the PD‑1 antibody penpulimab and chemotherapy, can improve responses in people with unresectable, recurrent, or metastatic HER2‑positive gastroesophageal adenocarcinoma.

  Recruiting Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Fuyang, Anhui and 38 other locations · NCT06767800

• New treatment for HER2-positive gastric cancer using rilvegostomig and chemotherapy

  This study is testing a new treatment combining rilvegostomig with chemotherapy for people with HER2-positive gastric cancer to see if it works better than current standard treatments.

  Recruiting at 253 sites Phase 3 AstraZeneca · Anchorage, Alaska and 303 other locations · NCT06764875

• Combination of Enfortumab Vedotin and Pembrolizumab with Surgery for Advanced Bladder Cancer

  This study is testing if a combination of two medications, enfortumab vedotin and pembrolizumab, can help people with advanced bladder cancer before they have surgery.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT06764095

• Combining Sigvotatug Vedotin and Pembrolizumab for Non-Small Cell Lung Cancer

  This study is testing a new combination of two treatments, Sigvotatug Vedotin and pembrolizumab, to see if it helps people with advanced non-small cell lung cancer feel better compared to just using pembrolizumab alone.

  Recruiting at 355 sites Phase 3 Pfizer · Fullerton, California and 388 other locations · NCT06758401

• Investigating ALE.P02 for treating specific solid tumors in adults

  This study is testing a new treatment called ALE.P02 to see if it can safely help adults with advanced solid tumors that have a specific marker called Claudin-1.

  Recruiting at 39 sites Phase 1/2 Alentis Therapeutics AG · Scottsdale, Arizona and 40 other locations · NCT06747585

• Assessing treatment outcomes of Pembrolizumab in Black patients with advanced lung cancer

  This study is testing if a combination of chemotherapy and Pembrolizumab can help Black patients with advanced lung cancer who haven't been treated before.

  Recruiting at 11 sites Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 10 other locations · NCT06745882

• Exploring immune responses in Hodgkin's lymphoma patients treated with pembrolizumab

  This study is trying to see how the immune system of patients with relapsed Hodgkin's lymphoma responds to the treatment pembrolizumab to help improve future therapies.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06733987

• Combining Pembrolizumab with Chemotherapy and Other Treatments for Advanced Lung Cancer

  This study is testing if combining the immunotherapy drug pembrolizumab with chemotherapy and other treatments can help people with untreated advanced lung cancer feel better and live longer.

  Recruiting at 37 sites Phase 2 Merck Sharp & Dohme LLC · Lexington, Kentucky and 40 other locations · NCT06731907

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination treatment for adults with advanced HER2-positive gastric cancer to see if it works better than the standard treatment.

  Recruiting at 219 sites Phase 3 Daiichi Sankyo · New Haven, Connecticut and 249 other locations · NCT06731478

• Combination treatment for recurrent head and neck cancer after pembrolizumab failure

  This study is testing a new combination treatment for adults with recurrent head and neck cancer who didn't respond to pembrolizumab to see if it can help them feel better and improve their health.

  Recruiting at 5 sites Phase 2 Centre Paul Strauss · Ars-Laquenexy and 4 other locations · NCT06725368

• Testing HM16390 for advanced or metastatic solid tumors

  This study is testing a new treatment called HM16390 for people with advanced or metastatic solid tumors who haven't had success with other therapies to see if it can help them.

  Recruiting at 7 sites Phase 1 Hanmi Pharmaceutical Company Limited · Los Angeles, California and 7 other locations · NCT06724016

• Testing M3T01 alone and with pembrolizumab or standard chemotherapies for advanced solid tumors

  This trial tests whether the antibody M3T01, by itself or with pembrolizumab or standard chemotherapies, is safe and might help adults with metastatic or unresectable solid tumors.

  Recruiting Phase 1 Providence Health & Services · Portland, Oregon · NCT06719362

• Combining Surufatinib with Gemcitabine, Cisplatin, and Durvalumab/Pembrolizumab for Advanced Biliary Tract Cancer

  This study is testing if adding a new drug called surufatinib to the standard treatment for advanced biliary tract cancer can help patients live longer and feel better.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT06708858

• Combining ASP-1929 photoimmunotherapy with pembrolizumab for treating recurrent head and neck cancer

  This study is testing if a new light-based treatment combined with pembrolizumab can help people with recurring head and neck cancer live longer compared to standard treatments.

  Recruiting at 21 sites Phase 3 Rakuten Medical, Inc. · Duarte, California and 21 other locations · NCT06699212

• Evaluating EIK1001 with Pembrolizumab for Advanced Melanoma

  This study is testing if a new drug called EIK1001, when combined with Pembrolizumab, can help people with advanced melanoma feel better compared to just using Pembrolizumab alone.

  Recruiting at 125 sites Phase 2/3 Eikon Therapeutics · Chandler, Arizona and 126 other locations · NCT06697301

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials of Pembrolizumab are recruiting right now?

394, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 65 countries. The most sites are in United States (260 trials), China (80 trials), South Korea (79 trials), Italy (74 trials), France (71 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 180, Phase 3: 72, Phase 1/2: 62, Phase 1: 51. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →